JetBlue Airways enters Tuesday's Q1 2026 results with short interest elevated and a stock that has given back nearly all of its recent recovery in a single week.
Nearly one in five free-float shares are sold short — SI % of FF runs at 18.8%, up roughly 6% over the past month. Despite that, the short squeeze threat looks limited for now. Utilization has climbed back to 35%, still well below the 52-week high of 49%, and cost to borrow has actually eased over the past month to just 0.36%, signalling ample room for new shorts to enter. Options positioning offers a counterpoint: the put/call ratio of 0.81 is only marginally above its 20-day average of 0.80, with a z-score barely above zero. That makes the options market look notably calm relative to the short interest picture — traders are not rushing to hedge a disaster scenario. The stock itself closed at $4.94, down 14% on the week but up 17% on the month, reflecting a volatile tape shaped more by macro airline sentiment than company-specific news.
The analyst debate has shifted notably bearish in recent months. Goldman Sachs cut its target to $3.50 at the start of April — well below the current price — while Citigroup trimmed from $6.00 to $4.40 in March and UBS also moved to $3.50. The mean consensus target of $4.71 effectively implies the stock is fairly valued here, and the lone buy rating against 11 holds underlines how little institutional enthusiasm exists. The ORTEX short score of 63.8 ranks in roughly the 92nd percentile of the universe, a reading consistent with meaningful bearish positioning. The one piece of structural relief: EPS momentum ranks in the 97th–98th percentile on both 30- and 90-day horizons, meaning forward earnings estimates have been rising sharply even as the stock has lagged. Bulls point to the JetForward restructuring plan and a leaner cost structure; bears focus on the airline's still-negative PE, a $9.2 billion enterprise value against an EV/EBITDA of 18x, and the fog of tariff-driven demand uncertainty.
Ownership adds a layer of intrigue. Activist investor Icahn Capital holds 9% of shares with no change reported since year-end, while a trust linked to Angelica Galkin owns a further 9.5% and added roughly 3.4 million shares as recently as early April — a meaningful vote of confidence from concentrated holders. Against that, C-suite insiders sold into strength in mid-April: the President, CFO, President/COO, and CTO all liquidated small tranches near $4.93–$5.46, part of routine award-and-sell activity but notable in proximity to the print. Previous earnings reactions show a pattern worth watching — Q3 2025 results sent the stock down 13.5% on the day and another 0.1% over the following week, while Q4 2025 saw a modest 0.8% decline on day one followed by a five-day recovery of nearly 10%.
The print will test whether JetForward cost savings are materialising fast enough to justify the sharp upward revision in forward EPS estimates — and whether management's revenue outlook holds in an environment where peer airlines like AAL and DAL have already guided cautiously.
See the live data behind this article on ORTEX.
Open JBLU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
